Published in J Inherit Metab Dis on June 08, 2010
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Anal Chem (2010) 1.34
Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform. Clin Chim Acta (2013) 1.01
Therapeutic approaches for lysosomal storage diseases. Ther Adv Endocrinol Metab (2010) 0.76
Newborn screening: how are we travelling, and where should we be going? J Inherit Metab Dis (2011) 0.76
A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS. Pediatrics (1963) 14.49
Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med (2001) 6.94
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med (2001) 4.28
Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N Engl J Med (2005) 4.26
Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med (2004) 4.15
Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem (2004) 4.10
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr (2004) 3.86
High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet (2006) 3.78
A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr (2006) 3.45
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab (2010) 2.99
Newborn screening for Krabbe disease: the New York State model. Pediatr Neurol (2009) 2.88
Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics (2008) 2.61
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med (2009) 2.53
Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem (2008) 2.48
Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics (2009) 2.44
Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem (2008) 2.34
Enzyme replacement for lysosomal diseases. Annu Rev Med (2006) 2.26
Preliminary report on a mass screening program for neonatal hypothyroidism. J Pediatr (1975) 2.25
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood (1996) 2.19
The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med (2009) 2.07
Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A (2000) 2.00
Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics (2008) 1.95
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr (2004) 1.94
The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis (2007) 1.94
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest (2006) 1.91
Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int (2006) 1.82
Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat (2009) 1.78
Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta (2001) 1.78
Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab (2007) 1.71
Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab (1977) 1.69
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet (2006) 1.65
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl (2002) 1.63
Newborn screening fact sheets. Pediatrics (2006) 1.62
Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy (2007) 1.60
Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics (2009) 1.56
Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci U S A (1977) 1.56
Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat (1995) 1.54
Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant (2007) 1.42
Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem (1993) 1.41
High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet (2009) 1.39
Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem (2006) 1.38
Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop (2003) 1.37
Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest (1998) 1.34
Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem (2001) 1.34
Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta (2004) 1.33
Newborn screening for lysosomal storage disorders. Mol Genet Metab (2006) 1.27
Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis (2001) 1.25
Barrier mechanisms in the brain, II. Immature brain. Clin Exp Pharmacol Physiol (1999) 1.20
Tandem mass spectrometry in the detection of inborn errors of metabolism for newborn screening. Methods Mol Biol (2007) 1.18
Substrate reduction therapy. Acta Paediatr Suppl (2008) 1.10
Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin (2006) 1.06
Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A (2008) 1.05
Diversity of mutations and distribution of single nucleotide polymorphic alleles in the human alpha-L-iduronidase (IDUA) gene. Genet Med (2003) 0.98
Diagnosis of cystic fibrosis after newborn screening: the Australasian experience--twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group. Pediatr Pulmonol (2005) 0.98
Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med (2006) 0.98
Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics (2007) 0.95
Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis (2007) 0.91
Early onset of lysosomal storage disease in a murine model of mucopolysaccharidosis type VII: undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Dev Pathol (2005) 0.90
Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis (2009) 0.90
The influence of newborn screening for cystic fibrosis on pulmonary outcomes in new South Wales. J Pediatr (2005) 0.88
Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr (2009) 0.87
Lysosomal storage diseases in non-immune hydrops fetalis pregnancies. Clin Chim Acta (2006) 0.84
Phenylketonuria: an update. Curr Opin Pediatr (2002) 0.76
Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov (2006) 0.76
Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med (2011) 3.21
Carnitine uptake defect (primary carnitine deficiency): risk in genotype-phenotype correlation. Hum Mutat (2013) 2.17
Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics (2008) 1.95
Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat (2009) 1.78
Somatic and germ-line mosaicism in Rubinstein-Taybi syndrome. Am J Med Genet A (2009) 1.74
Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy (2007) 1.60
Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics (2009) 1.56
Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med (2012) 1.44
Distal arthrogryposis in two sisters born to different fathers. Am J Med Genet A (2004) 1.38
A step-wise diagnosis of fragile X syndrome in Taiwan. Acta Paediatr Taiwan (2004) 1.38
Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. J Med Genet (2011) 1.33
Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet (2011) 1.23
Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci Transl Med (2012) 1.22
Lung toxicity of hydroxypropyl-β-cyclodextrin infusion. Mol Genet Metab (2013) 1.19
Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clin Chim Acta (2010) 1.16
Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis (2013) 1.14
Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening. Mol Genet Metab (2009) 1.13
Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis (2010) 1.13
Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous origin. Genet Med (2012) 1.02
A promoter sequence variant of ZNF750 is linked with familial psoriasis. J Invest Dermatol (2008) 1.02
Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. Mol Genet Metab (2009) 0.99
Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol (2013) 0.99
Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis (2012) 0.99
Living-related liver transplantation for methylmalonic acidemia: report of one case. Acta Paediatr Taiwan (2003) 0.94
Eye anomalies and neurological manifestations in patients with PAX6 mutations. Mol Vis (2009) 0.94
KIF21A gene c.2860C>T mutation in congenital fibrosis of extraocular muscles type 1 and 3. Mol Vis (2005) 0.94
Enzymatic activity of methionine adenosyltransferase variants identified in patients with persistent hypermethioninemia. Mol Genet Metab (2010) 0.94
Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab (2010) 0.93
Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res (2006) 0.93
Cystathionine gamma-lyase: Clinical, metabolic, genetic, and structural studies. Mol Genet Metab (2009) 0.93
CCL18 as an alternative marker in Gaucher and Niemann-Pick disease with chitotriosidase deficiency. Blood Cells Mol Dis (2009) 0.92
Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr (2011) 0.91
Identification of novel mutations in the SLC25A15 gene in hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome: a clinical, molecular, and functional study. Hum Mutat (2009) 0.91
Regulation of the dopaminergic system in a murine model of aromatic L-amino acid decarboxylase deficiency. Neurobiol Dis (2012) 0.90
Efficacy and safety of intermittent hemodialysis in infants and young children with inborn errors of metabolism. Pediatr Nephrol (2013) 0.89
Rapid progressive course of later-onset Pompe disease in Chinese patients. Mol Genet Metab (2011) 0.89
Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review. Eur J Pediatr (2007) 0.89
Enzyme replacement therapy for mucopolysaccharidosis VI--experience in Taiwan. J Inherit Metab Dis (2010) 0.88
Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab (2012) 0.88
Alpha-galactosidase activity should be examined in patients with proteinuria: what have we learned from a family affected with Fabry disease? Nephrol Dial Transplant (2005) 0.87
The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathol Commun (2014) 0.87
Reversal of cardiac dysfunction after enzyme replacement in patients with infantile-onset Pompe disease. J Pediatr (2009) 0.87
Mutation of mitochondrial DNA G13513A presenting with Leigh syndrome, Wolff-Parkinson-White syndrome and cardiomyopathy. Pediatr Neonatol (2008) 0.87
Early pathologic changes and responses to treatment in patients with later-onset Pompe disease. Pediatr Neurol (2012) 0.87
Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. J Hum Genet (2012) 0.85
Analysis of lyso-globotriaosylsphingosine in dried blood spots. Ann Lab Med (2013) 0.85
Complex rearrangements between chromosomes 6, 10, and 11 with multiple deletions at breakpoints. Am J Med Genet A (2010) 0.84
Caloric restriction in Alström syndrome prevents hyperinsulinemia. Am J Med Genet A (2009) 0.84
Fatty Acid oxidation disorders in a chinese population in taiwan. JIMD Rep (2013) 0.84
Newborn screening for citrin deficiency and carnitine uptake defect using second-tier molecular tests. BMC Med Genet (2013) 0.84
Clinical features and genetic analysis of Taiwanese patients with the hyper IgM syndrome phenotype. Pediatr Infect Dis J (2013) 0.83
Distribution, clinical features and treatment in Taiwanese patients with symptomatic primary immunodeficiency diseases (PIDs) in a nationwide population-based study during 1985-2010. Immunobiology (2011) 0.83
De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma. Ann Allergy Asthma Immunol (2006) 0.83
Late onset of symptoms in an atypical patient with the cblJ inborn error of vitamin B12 metabolism: diagnosis and novel mutation revealed by exome sequencing. Mol Genet Metab (2012) 0.83
Computational analysis of a novel mutation in ETFDH gene highlights its long-range effects on the FAD-binding motif. BMC Struct Biol (2011) 0.82
Tandem mass neonatal screening in Taiwan--report from one center. J Formos Med Assoc (2006) 0.82
Unusual spinal cord lesions in late-onset non-ketotic hyperglycinemia. J Child Neurol (2011) 0.82
SLC25A13 gene mutations in Taiwanese patients with non-viral hepatocellular carcinoma. Mol Genet Metab (2011) 0.82
Hypertrophic cardiomyopathy in pompe disease is not limited to the classic infantile-onset phenotype. JIMD Rep (2014) 0.82
Clinical aspects and genetic analysis of taiwanese patients with wiskott-Aldrich syndrome protein mutation: the first identification of x-linked thrombocytopenia in the chinese with novel mutations. J Clin Immunol (2010) 0.81
Identification of CpG methylation of the SNRPN gene by methylation-specific multiplex PCR. Electrophoresis (2009) 0.81
Prominent vacuolation of the eyelid levator muscle in an early-treated child with infantile-onset Pompe disease. Muscle Nerve (2014) 0.81
Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: correlation with intelligence assessment. AJNR Am J Neuroradiol (2004) 0.81
Chubby face and the biochemical parameters for the early diagnosis of neonatal intrahepatic cholestasis caused by citrin deficiency. J Pediatr Gastroenterol Nutr (2008) 0.81
Promising outcomes in glutaric aciduria type I patients detected by newborn screening. Metab Brain Dis (2012) 0.80
Early detection of glutaric aciduria type I by newborn screening in Taiwan. J Formos Med Assoc (2008) 0.80
Screening of mitochondrial DNA mutations in subjects with non-syndromic familial hearing impairment in Taiwan. Acta Paediatr Taiwan (2003) 0.80
Newborn screening healthcare information system based on service-oriented architecture. J Med Syst (2009) 0.80
Changes in incidence and sex ratio of glucose-6-phosphate dehydrogenase deficiency by population drift in Taiwan. Southeast Asian J Trop Med Public Health (2008) 0.80
Adrenoleukodystrophy initially diagnosed as idiopathic Addison's disease in two patients: the importance of early testing. J Formos Med Assoc (2003) 0.79
Serial cytokine expressions in infants with incontinentia pigmenti. Immunobiology (2012) 0.79
Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening. JIMD Rep (2015) 0.78
Treatment of congenital neurotransmitter deficiencies by intracerebral ventricular injection of an adeno-associated virus serotype 9 vector. Hum Gene Ther (2014) 0.78
Web-based newborn screening system for metabolic diseases: machine learning versus clinicians. J Med Internet Res (2013) 0.78
Novel heterozygous tissue-nonspecific alkaline phosphatase (TNAP) gene mutations causing lethal perinatal hypophosphatasia. J Bone Miner Metab (2011) 0.78
Torsade de pointes ventricular tachycardia during elective intubation in a patient with Pompe disease. Paediatr Anaesth (2008) 0.78
Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study. J Formos Med Assoc (2002) 0.78
Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease. Mol Genet Metab (2010) 0.77
Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease. J Formos Med Assoc (2002) 0.77
Mitochondrial depletion causes neonatal-onset leigh syndrome, myopathy, and renal tubulopathy. J Child Neurol (2013) 0.77